Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Akebia Therapeutics, Inc. (AKBA) vs Cardiol Therapeutics Inc. (CRDL)

Akebia Therapeutics, Inc. and Cardiol Therapeutics Inc. are both Drug Manufacturers Specialty & Generic companies. Akebia Therapeutics, Inc. is the larger, with a market value of $254.7M against $202.1M — 1.3× the size. Cardiol Therapeutics Inc. has the higher net margin (0.00% vs −13.5%) and the higher return on invested capital (0.00% vs 0.00%). Across the 13 metrics below, Akebia Therapeutics, Inc. leads on 9 and Cardiol Therapeutics Inc. on 4.

Valuation

Metric AKBA CRDL Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.14
P/S 1.11 n/m 2.25
P/B 9.70 11.32 1.90
Price to free cash flow 6.03 n/m 16.54
EV/EBITDA n/m n/m 12.29
EV/Sales 0.62 n/m 2.56
Earnings yield (12.00%) (14.62%) (2.99%)
Free cash flow yield 16.59% (8.77%) 0.00%

Profitability

Metric AKBA CRDL Drug Manufacturers Specialty & Generic median
Gross margin 79.63% 0.00% 53.94%
Operating margin (6.90%) 0.00% 0.00%
Net margin (13.54%) 0.00% 0.00%
Free cash flow margin 18.38% 0.00% 0.00%
Return on equity (109.38%) (171.13%) (0.40%)
Return on assets (8.53%) (124.40%) (3.32%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric AKBA CRDL Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 7.52% — 10.01%
EPS growth (last fiscal year) 93.94% 24.32% —
Revenue growth, 5-year CAGR (4.33%) — 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric AKBA CRDL Drug Manufacturers Specialty & Generic median
Debt to equity 1.98 0.00 0.05
Current ratio 1.43 5.55 2.31
Net debt to EBITDA (5.51) 0.62 0.85

Dividend

Metric AKBA CRDL Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric AKBA CRDL Drug Manufacturers Specialty & Generic median
Market cap 254.66m 202.10m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack